Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hypoplastic acute myelogenous leukaemia.

M E Beard, C J Bateman, D C Crowther

    British Journal of Haematology
    |October 1, 1975
    PubMed
    Summary

    Hypoplastic acute myelogenous leukemia may progress slowly. Avoid chemotherapy unless disease advances rapidly or complications arise; chemotherapy may induce remission, especially for infections.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Identification of novel modifiers of Aβ toxicity by transcriptomic analysis in the fruitfly.

    Scientific reports·2013
    Same author

    Chemotherapy of Hodgkin's Disease with Cyclophosphamide, Vinblastine, and Procarbazine.

    British medical journal·2010
    Same author

    Clinical validation of an autoantibody test for lung cancer.

    Annals of oncology : official journal of the European Society for Medical Oncology·2010
    Same author

    Alpha-helix targeting reduces amyloid-beta peptide toxicity.

    Proceedings of the National Academy of Sciences of the United States of America·2009
    Same author

    Plasma and CSF serpins in Alzheimer disease and dementia with Lewy bodies.

    Neurology·2007
    Same author

    Molecular mousetraps and the serpinopathies.

    Biochemical Society transactions·2005

    Area of Science:

    • Hematology
    • Oncology

    Background:

    • Acute myelogenous leukemia (AML) typically presents aggressively.
    • Hypoplastic AML is a rare subtype with distinct clinical characteristics.

    Observation:

    • Nine cases of hypoplastic AML were analyzed for clinical course, diagnosis, and management.
    • These cases exhibited a potentially slow-progressing disease course.

    Findings:

    • Anti-leukemic chemotherapy is generally not recommended for hypoplastic AML unless rapid progression or specific complications are present.
    • Chemotherapy, when indicated for complications like severe infections, can lead to prompt and prolonged remissions.

    Implications:

    • This suggests a conservative management approach for hypoplastic AML, prioritizing supportive care.

    Related Experiment Videos

  • Early intervention with chemotherapy in specific scenarios may yield favorable outcomes, challenging traditional AML treatment paradigms.